Selenium and zinc deficiency Nutritional, Metabolic, Endocrine Selenium and zinc deficiency
Conditions
Interventions
Using a computer-based randomisation programme, participant households will be randomly allocated in a 1:1 ratio to either the intervention or control arm. The intervention arm will receive teff flour
Sponsors
London School of Hygiene & Tropical Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Household level: 1. Household members include at least one non-pregnant woman of reproductive age (20-45 years) and at least one school-aged child (5-10 years) 2. Household typically prepares and consumes meals at home 3. Household head agrees that the household will receive and all members consume teff flour for the 60 day flour distribution period 4. No confirmed, suspected, or probable cases of COVID-19 in the household in the past 14 days Individual level: 1. Individual is not pregnant (self-reported) and is apparently healthy 2. Planning to be in residence in the household during the intervention period 3. Participant woman of reproductive age is willing and able to provide consent, and the caretaker of the participant school-aged child is willing and able to provide assent
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Blood plasma selenium concentration (in µg/l) measured using Inductively Coupled Plasma Mass Spectrometry (ICPMS) with plasma samples collected at endline | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures: 1. The Relative Risk of selenium deficiency, defined as <70µg/l at endline 2. Plasma zinc concentration (mg/l) measured by ICPMS at endline 3. Plasma copper to zinc molar ratio measured using plasma samples at endline _____ Previous secondary outcome measures: 1. The Relative Risk of selenium deficiency, defined using established thresholds for the optimal activity of Glutathione peroxidase 3 (GPx-3) (<84.9?µg l-1) and iodothyronine deiodinase (IDI) (<64.8?µg l-1) at endline 2. Plasma zinc concentration (mg l-1) before and after correction for inflammation status measured using ICPMS at endline 3. Plasma copper to zinc molar ratio measured using plasma samples at endline 4. Plasma Linoleic Acid to Dihomo-?-Linolenic Acid ratio (LA:DGLA) measured using plasma samples at endline 5. Plasma Arachidonic acid to Dihomo-?-Linolenic Acid ratio (AA:DGLA) measured using plasma samples at endline 6. Concentration of haemoglobin in whole venous blood (g dl-1) measured in the field using a portable HemoCue Hb301+ (HemoCue AB, Ängelholm, Sweden) at endline | — |
Countries
Ethiopia
Contacts
Public ContactEdward Joy
Outcome results
None listed